While the majority of pregnant women experience nausea and/or vomiting during the first trimester of pregnancy, a smaller subset of women — around 1% — experience more severe and intractable vomiting, or hyperemesis gravidarum [...]
In women, testosterone is produced by the ovaries in small amounts; however, levels of testosterone decline with age, independent of menopausal status. Low-dose testosterone has been used to improve sexual functioning in women with [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Every Wednesday, we have the pleasure of holding virtual rounds with other clinicians to discuss important topics in reproductive psychiatry. So many great questions! Last week, one of our participants asked about using light therapy [...]
In March, when the COVID-19 pandemic hit Massachusetts, centers providing infertility services were forced to hit the pause button, leaving many couples in the United States in the lurch. On March 17, the American Society [...]
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
Nausea and vomiting of pregnancy (NVP) affects up to 80% of women during the first trimester. A smaller proportion of women (0.3%–3.0%) experience severe vomiting or hyperemesis gravidarum. While milder cases of nausea and [...]
We have really enjoyed our weekly virtual rounds. It’s been a great opportunity to meet other perinatal psychiatrists in the community, and discussions with new people always brings up interesting clinical questions. Last week [...]
There is excellent data to support the use of selective serotonin and serotonin- norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
